

# Alessandro Federico

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2818681/publications.pdf>

Version: 2024-02-01

185  
papers

7,836  
citations

61984

43  
h-index

56724

83  
g-index

189  
all docs

189  
docs citations

189  
times ranked

11281  
citing authors

#	ARTICLE	IF	CITATIONS
1	The analysis of alcohol consumption during the severe acute respiratory syndrome Coronavirus 2 Italian lockdown. <i>Minerva Medica</i> , 2023, 113, .	0.9	5
2	Beneficial Effects of Silybin Treatment After Viral Eradication in Patients With HCV-Related Advanced Chronic Liver Disease: A Pilot Study. <i>Frontiers in Pharmacology</i> , 2022, 13, 824879.	3.5	0
3	The Lesson from the First Italian Lockdown: Impacts on Anxiety and Depressive Symptoms and Sleep Quality in Patients with Remission of Inflammatory Bowel Disease. <i>Reviews on Recent Clinical Trials</i> , 2022, 17, 109-119.	0.8	17
4	Rare ATG7 genetic variants predispose patients to severe fatty liver disease. <i>Journal of Hepatology</i> , 2022, 77, 596-606.	3.7	38
5	Gut microbiota correlates with antitumor activity in patients with <scp>mCRC</scp> and <scp>NSCLC</scp> treated with cetuximab plus avelumab. <i>International Journal of Cancer</i> , 2022, 151, 473-480.	5.1	24
6	Anorectal Function with High-Resolution Anorectal Manometry in Active Ulcerative Colitis and after Remission: A Pilot Study. <i>Reviews on Recent Clinical Trials</i> , 2022, 17, 97-102.	0.8	0
7	The Role of Insulin Resistance in Fueling NAFLD Pathogenesis: From Molecular Mechanisms to Clinical Implications. <i>Journal of Clinical Medicine</i> , 2022, 11, 3649.	2.4	19
8	Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. <i>Journal of Hepatology</i> , 2021, 74, 775-782.	3.7	193
9	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. <i>Journal of Hepatology</i> , 2021, 74, 340-349.	3.7	38
10	May chronic cough in chronic obstructive pulmonary disease be a contraindication of Percutaneous Endoscopic Gastrostomy placement: a case report. <i>BMC Gastroenterology</i> , 2021, 21, 31.	2.0	2
11	Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer. <i>Medical Oncology</i> , 2021, 38, 13.	2.5	13
12	Dietary Polyphenols and Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2021, 13, 494.	4.1	70
13	The Role of Resveratrol in Liver Disease: A Comprehensive Review from In Vitro to Clinical Trials. <i>Nutrients</i> , 2021, 13, 933.	4.1	50
14	An Italian Survey on Dietary Habits and Changes during the COVID-19 Lockdown. <i>Nutrients</i> , 2021, 13, 1197.	4.1	54
15	The Role of Fructose in Non-Alcoholic Steatohepatitis: Old Relationship and New Insights. <i>Nutrients</i> , 2021, 13, 1314.	4.1	34
16	Nutrigenomics and Nutrigenetics in Metabolic- (Dysfunction) Associated Fatty Liver Disease: Novel Insights and Future Perspectives. <i>Nutrients</i> , 2021, 13, 1679.	4.1	14
17	Oral Microbiota and Salivary Levels of Oral Pathogens in Gastro-Intestinal Diseases: Current Knowledge and Exploratory Study. <i>Microorganisms</i> , 2021, 9, 1064.	3.6	32
18	Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology. <i>Journal of Hepatology</i> , 2021, 75, 1355-1366.	3.7	15

#	ARTICLE	IF	CITATIONS
19	Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study. <i>Cancers</i> , 2021, 13, 3810.	3.7	8
20	How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 4719.	3.7	7
21	Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression. <i>International Journal of Molecular Sciences</i> , 2021, 22, 436.	4.1	40
22	Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis. <i>Metabolomics</i> , 2021, 17, 12.	3.0	37
23	PNPLA3, TM6SF2, and MBOAT7 Influence on Nutraceutical Therapy Response for Non-alcoholic Fatty Liver Disease: A Randomized Controlled Trial. <i>Frontiers in Medicine</i> , 2021, 8, 734847.	2.6	10
24	Evaluation of the Efficacy and Safety of a Compound of Micronized Flavonoids in Combination With Vitamin C and Extracts of <i>Centella asiatica</i> , <i>Vaccinium myrtillus</i> , and <i>Vitis vinifera</i> for the Reduction of Hemorrhoidal Symptoms in Patients With Grade II and III Hemorrhoidal Disease: A Retrospective Real-Life Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 773320.	3.5	4
25	Extra-Gastric Manifestations of <i>Helicobacter pylori</i> Infection. <i>Journal of Clinical Medicine</i> , 2020, 9, 3887.	2.4	46
26	The Bisphenol A Induced Oxidative Stress in Non-Alcoholic Fatty Liver Disease Male Patients: A Clinical Strategy to Antagonize the Progression of the Disease. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 3369.	2.6	16
27	Alcohol associated liver disease 2020: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2020, 52, 374-391.	0.9	29
28	Adherence and Effects Derived from FODMAP Diet on Irritable Bowel Syndrome: A Real Life Evaluation of a Large Follow-Up Observation. <i>Nutrients</i> , 2020, 12, 928.	4.1	21
29	Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort. <i>Hepatology International</i> , 2020, 14, 362-372.	4.2	8
30	Non- $\epsilon$ -bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real-life study. <i>Helicobacter</i> , 2020, 25, e12694.	3.5	20
31	Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 26, 261-268.	0.9	20
32	Light Alcohol Drinking and the Risk of Cancer Development: A Controversial Relationship. <i>Reviews on Recent Clinical Trials</i> , 2020, 15, 164-177.	0.8	4
33	Critical review on the use and abuse of alcohol. When the dose makes the difference. <i>Minerva Medica</i> , 2020, 111, 344-353.	0.9	6
34	Urotensin II receptor expression in patients with ulcerative colitis: a pilot study. <i>Minerva Gastroenterologica E Dietologica</i> , 2020, 66, 23-28.	2.2	3
35	Novel Insights into the Genetic Landscape of Nonalcoholic Fatty Liver Disease. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 2755.	2.6	28
36	Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-12.	4.0	43

#	ARTICLE	IF	CITATIONS
37	P.04.5 EFFECT OF BISPENOL A EXPOSURE ON HEP-G2 CELLS AND ITS INTERFERENCE IN CELL PROLIFERATION, OXIDATIVE STRESS AND OXIDATIVE METABOLISM OF STEROID HORMONES. Digestive and Liver Disease, 2019, 51, e172-e173.	0.9	0
38	Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives. International Journal of Environmental Research and Public Health, 2019, 16, 4334.	2.6	21
39	Diet and Non-Alcoholic Fatty Liver Disease: The Mediterranean Way. International Journal of Environmental Research and Public Health, 2019, 16, 3011.	2.6	86
40	Chemical Effect of Bisphenol A on Non-Alcoholic Fatty Liver Disease. International Journal of Environmental Research and Public Health, 2019, 16, 3134.	2.6	39
41	P.07.22 HIGH RESOLUTION ANORECTAL MANOMETRY FOR DETERMINATION OF ANORECTAL FUNCTION IN ULCERATIVE COLITIS DURING DISEASE ACTIVITY AND AFTER REMISSION. Digestive and Liver Disease, 2019, 51, e231.	0.9	0
42	NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome. International Journal of Environmental Research and Public Health, 2019, 16, 3415.	2.6	90
43	Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study. Liver International, 2019, 39, 1852-1859.	3.9	31
44	Role of Bisphenol A on cell biology: effect on proliferation, oxidative stress and steroid hormones metabolism of HepG2 cells. Digestive and Liver Disease, 2019, 51, e46.	0.9	0
45	Silybin-Induced Apoptosis Occurs in Parallel to the Increase of Ceramides Synthesis and miRNAs Secretion in Human Hepatocarcinoma Cells. International Journal of Molecular Sciences, 2019, 20, 2190.	4.1	20
46	Ameliorative effect of Silybin on bisphenol A induced oxidative stress, cell proliferation and steroid hormones oxidation in HepG2 cell cultures. Scientific Reports, 2019, 9, 3228.	3.3	34
47	Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment. Antiviral Therapy, 2019, 24, 485-493.	1.0	5
48	Liver fibrosis: which are independent predictors?. Minerva Medica, 2019, 110, 183-184.	0.9	5
49	Sustained Virological Response by Direct Antiviral Agents in HCV Leads to an Early and Significant Improvement of Liver Fibrosis. Antiviral Therapy, 2018, 23, 129-138.	1.0	33
50	Forecasting liver disease burden. Digestive and Liver Disease, 2018, 50, 10-11.	0.9	0
51	Role of bisphenol A as environmental factor in the promotion of non-alcoholic fatty liver disease: in vitro and clinical study. Alimentary Pharmacology and Therapeutics, 2018, 47, 826-837.	3.7	51
52	Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin's lymphoma. Hepatology, 2018, 67, 48-55.	7.3	76
53	Peptide Hp(2-20) accelerates healing of TNBS-induced colitis in the rat. United European Gastroenterology Journal, 2018, 6, 1428-1436.	3.8	14
54	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet, The, 2018, 391, 2417-2429.	13.7	345

#	ARTICLE	IF	CITATIONS
55	Vascular Endothelial Dysfunction in Inflammatory Bowel Diseases: Pharmacological and Nonpharmacological Targets. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-12.	4.0	28
56	Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the “underwater portion of the iceberg” matter to reach the WHO HCV eliminating goals in the high HCV prevalent countries?. <i>Journal of Hepatology</i> , 2018, 68, S149-S150.	3.7	0
57	Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-14.	4.0	447
58	Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota. <i>Neoplasia</i> , 2018, 20, 721-733.	5.3	65
59	Forecasting Hepatitis C liver disease burden on real-life data. Does the “hidden iceberg” matter to reach the elimination goals?. <i>Liver International</i> , 2018, 38, 2190-2198.	3.9	33
60	A Real-Life Study of New Antiviral Therapies in a High Prevalence Geographical Area for Hepatitis C Virus Infection. <i>Hepatitis Monthly</i> , 2018, In Press, .	0.2	1
61	Distinct metaplastic and inflammatory phenotypes in autoimmune and adenocarcinoma-associated chronic atrophic gastritis. <i>United European Gastroenterology Journal</i> , 2017, 5, 37-44.	3.8	27
62	“Non alcoholic fatty liver disease and eNOS dysfunction in humans” <i>BMC Gastroenterology</i> , 2017, 17, 35.	2.0	45
63	Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required?. <i>Digestive and Liver Disease</i> , 2017, 49, 197-201.	0.9	5
64	Long-term albumin administration improves survival in patients with decompensated cirrhosis: final results of the “ANSWER” study. <i>Journal of Hepatology</i> , 2017, 66, S93.	3.7	9
65	P.09.8: Role of Bisphenol a as Environmental Factor in the Promotion of Non-Alcoholic Fatty Liver Disease: In VITRO and in VIVO Protective Effects of Silybin. <i>Digestive and Liver Disease</i> , 2017, 49, e190.	0.9	1
66	Human exposure to Bisphenol A and liver health status: Quantification of urinary and circulating levels by LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 140, 105-112.	2.8	24
67	ITPase Activity Modulates the Severity of Anaemia in HCV-Related Cirrhosis Treated with Ribavirin-Containing Interferon-Free Regimens. <i>Antiviral Therapy</i> , 2017, 22, 551-558.	1.0	12
68	Hospital dismissal data sheets on alcoholic liver diseases into three first aid divisions: A southern Italy survey. <i>Digestive and Liver Disease</i> , 2017, 49, e237-e238.	0.9	0
69	OC.08.6: Prevalence of Ultrasonographic Enthesitis in Patients with Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2017, 49, e98-e99.	0.9	0
70	Diagnostic and therapeutic approaches of mixed cryoglobulinemia in PITER (Piattaforma Italiana per lo Tj ETQq0 0 0 rgBT /Overlock 10 T	3.7	1
71	P.08.8: Silybin in Combination with Regorafenib as a Novel Potential Strategy for the Treatment of Metastatic Colorectal Cancer Patients. <i>Digestive and Liver Disease</i> , 2017, 49, e181-e182.	0.9	1
72	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434.	8.1	15

#	ARTICLE	IF	CITATIONS
73	Mediterranean diet and nonalcoholic fatty liver disease: molecular mechanisms of protection. International Journal of Food Sciences and Nutrition, 2017, 68, 18-27.	2.8	69
74	Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years. Molecules, 2017, 22, 191.	3.8	301
75	Qualitative and Quantitative Evaluation of Dietary Intake in Patients with Non-Alcoholic Steatohepatitis. Nutrients, 2017, 9, 1074.	4.1	18
76	The Role of Stress in Inflammatory Bowel Diseases. Current Pharmaceutical Design, 2017, 23, 3997-4002.	1.9	45
77	Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer. Oncotarget, 2017, 8, 68305-68316.	1.8	27
78	Urotensin-II Receptor: A Double Identity Receptor Involved in Vasoconstriction and in the Development of Digestive Tract Cancers and other Tumors. Current Cancer Drug Targets, 2017, 17, 109-121.	1.6	17
79	A Long-term Treatment with Silybin in Patients with Non-alcoholic Steatohepatitis Stimulates Catalase Activity in Human Endothelial Cells. In Vivo, 2017, 31, 609-618.	1.3	13
80	Gut microbiota and the liver. Minerva Gastroenterology, 2017, 63, 385-398.	0.5	27
81	Gut microbiota, obesity and metabolic disorders. Minerva Gastroenterology, 2017, 63, 337-344.	0.5	34
82	Amelanotic metastatic melanoma of the stomach presenting with iron deficiency anemia. Acta Gastro-Enterologica Belgica, 2017, 80, 327-328.	1.0	0
83	Postoperative Changes in Fecal Bacterial Communities and Fermentation Products in Obese Patients Undergoing Bilio-Intestinal Bypass. Frontiers in Microbiology, 2016, 7, 200.	3.5	94
84	Pharmacotherapy of alcoholic liver disease in clinical practice. International Journal of Clinical Practice, 2016, 70, 119-131.	1.7	24
85	P.01.4 ENDOCAN AS SERUM MARKER OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND/OR TYPE 2 DIABETES. Digestive and Liver Disease, 2016, 48, e131.	0.9	0
86	Crohn's disease and skin. United European Gastroenterology Journal, 2016, 4, 165-171.	3.8	10
87	Gender Differences in HCV Chronic Liver Disease: A Real Life Evaluation in Piter (Piattaforma Italiana) Tj ETQq1 1 0.784314 rgBT /Overpo S618-S619.	3.7	4
88	Impact of SVR and Type 2 Diabetes Mellitus on liver stiffness and liver functionality in HCV infected patients with severe liver disease treated with DAA: A real life study. Digestive and Liver Disease, 2016, 48, e234.	0.9	0
89	P.04.6 PREVALENCE OF H. PYLORI INFECTION IN SEXUAL PARTNERS OF H. PYLORI INFECTED SUBJECTS: ROLE OF GASTROESOPHAGEAL REFLUX. Digestive and Liver Disease, 2016, 48, e145.	0.9	0
90	P.10.2 EFFECTS OF SILYBIN ADMINISTRATION ON THE REDOX STATE AND OXIDATIVE STRESS RESPONSE OF HUMAN ENDOTHELIAL CELLS IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS. Digestive and Liver Disease, 2016, 48, e178.	0.9	1

#	ARTICLE	IF	CITATIONS
91	P.10.1 REACTIVATION OF HEPATITIS B VIRUS IN CANCER PATIENTS TREATED WITH CHEMOTHERAPY FOR SOLID TUMORS. IS THE PROPHYLAXIS REALLY REQUIRED?. Digestive and Liver Disease, 2016, 48, e177.	0.9	0
92	AISF position paper on liver disease and pregnancy. Digestive and Liver Disease, 2016, 48, 120-137.	0.9	32
93	Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence. Translational Research, 2016, 167, 116-124.	5.0	73
94	Gut-Brain Axis in Gastric Mucosal Damage and Protection. Current Neuropharmacology, 2016, 14, 959-966.	2.9	27
95	Alcoholic Liver Disease and Hepatitis C Chronic Infection. Reviews on Recent Clinical Trials, 2016, 11, 201-207.	0.8	7
96	Alcoholic Hepatitis: Pathogenesis, Diagnosis and Treatment. Reviews on Recent Clinical Trials, 2016, 11, 159-166.	0.8	30
97	Epidemiology and Natural History of Alcoholic Liver Disease. Reviews on Recent Clinical Trials, 2016, 11, 167-174.	0.8	52
98	Impact of Telaprevir in HCV Patients with Cirrhosis and RVR: Real-Life Data from Boceprevir or Telaprevir based "Triple Therapy" Experience in Southern Italy. Reviews on Recent Clinical Trials, 2016, 11, 306-316.	0.8	4
99	Gastrointestinal Hormones, Intestinal Microbiota and Metabolic Homeostasis in Obese Patients: Effect of Bariatric Surgery. In Vivo, 2016, 30, 321-30.	1.3	47
100	The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: role of endothelial dysfunction. European Review for Medical and Pharmacological Sciences, 2016, 20, 4731-4741.	0.7	43
101	Telaprevir may induce adverse cutaneous reactions by a T cell immune-mediated mechanism. Annals of Hepatology, 2015, 14, 420-424.	1.5	7
102	<i>Helicobacter pylori</i> infection but not small intestinal bacterial overgrowth may play a pathogenic role in rosacea. United European Gastroenterology Journal, 2015, 3, 17-24.	3.8	72
103	Two-week, high-dose proton pump inhibitor, moxifloxacin triple <i>Helicobacter pylori</i> therapy after failure of standard triple or non-bismuth quadruple treatments. Digestive and Liver Disease, 2015, 47, 108-113.	0.9	22
104	Long-term use of human albumin for the treatment of ascites in patients with hepatic cirrhosis: The interim analysis of the ANSWER study. Digestive and Liver Disease, 2015, 47, e6.	0.9	3
105	The patterns of reflux can affect regression of non-dysplastic and low-grade dysplastic Barrett's esophagus after medical and surgical treatment: a prospective case-control study. Surgical Endoscopy and Other Interventional Techniques, 2015, 29, 648-657.	2.4	8
106	ENOS dysfunction in Steatosis and Steatohepatitis. Digestive and Liver Disease, 2015, 47, e55.	0.9	0
107	Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis. Oncology Letters, 2015, 9, 1628-1632.	1.8	25
108	<i>Helicobacter pylori</i> second-line rescue therapy with levofloxacin and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Alimentary Pharmacology and Therapeutics, 2015, 41, 768-775.	3.7	91



#	ARTICLE	IF	CITATIONS
109	Non Alcoholic Fatty Liver: Epidemiology and Natural History. Reviews on Recent Clinical Trials, 2015, 9, 126-133.	0.8	215
110	Rapid Virological Response Represents the Highest Prediction Factor of Response to Antiviral Treatment in HCV-Related Chronic Hepatitis: a Multicenter Retrospective Study. Hepatitis Monthly, 2015, 15, e18640.	0.2	7
111	Telaprevir may induce adverse cutaneous reactions by a T cell immune-mediated mechanism. Annals of Hepatology, 2015, 14, 420-4.	1.5	4
112	Polydatin administration improves serum biochemical parameters and oxidative stress markers during chronic alcoholism: a pilot study. In Vivo, 2015, 29, 405-8.	1.3	11
113	The effects of alcohol on gastrointestinal tract, liver and pancreas: evidence-based suggestions for clinical management. European Review for Medical and Pharmacological Sciences, 2015, 19, 1922-40.	0.7	10
114	A pilot study on the ability of clinoptilolite to absorb ethanol in vivo in healthy drinkers: effect of gender. Journal of Physiology and Pharmacology, 2015, 66, 441-7.	1.1	7
115	Silybin-Phosphatidylcholine Complex Protects Human Gastric and Liver Cells from Oxidative Stress. In Vivo, 2015, 29, 569-75.	1.3	18
116	Serum Oxidative Stress Markers and Lipidomic Profile to Detect NASH Patients Responsive to an Antioxidant Treatment: A Pilot Study. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-8.	4.0	66
117	Urotensinâ€œ receptor is overâ€œexpressed in colon cancer cell lines and in colon carcinoma in humans. European Journal of Clinical Investigation, 2014, 44, 285-294.	3.4	22
118	Eradication of <i>Helicobacter pylori</i> infection: Which regimen first?. World Journal of Gastroenterology, 2014, 20, 665.	3.3	36
119	Optimized contrastâ€œenhanced ultrasonography for characterization of focal liver lesions in cirrhosis: A singleâ€œcenter retrospective study. United European Gastroenterology Journal, 2014, 2, 279-287.	3.8	29
120	P.14.5 THE ROLE OF HELICOBACTER PYLORI INFECTION AND SMALL INTESTINAL BACTERIAL OVERGROWTH IN ROSACEA. Digestive and Liver Disease, 2014, 46, S110.	0.9	1
121	P.17.9 TELAPREVIR- OR BOCEPREVIR-BASED TRIPLE-THERAPY IN PATIENTS WITH HCV INFECTION GENOTYPE 1: ON-TREATMENT EFFICACY AND DATA ON SAFETY. Digestive and Liver Disease, 2014, 46, S123.	0.9	0
122	P070 Healing of TNBS-induced colitis in the rat by peptide Hp(2-20). Journal of Crohn's and Colitis, 2014, 8, S91-S92.	1.3	0
123	New silibinin glyco-conjugates: Synthesis and evaluation of antioxidant properties. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5147-5149.	2.2	21
124	Pegylated interferon $\pm$ plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency. Digestive and Liver Disease, 2014, 46, 826-832.	0.9	12
125	No differences of response to telaprevir based therapy in cirrhotic and non cirrhotic patients with RVR: Real life data from South Italy. Digestive and Liver Disease, 2014, 46, e134-e135.	0.9	0
126	P.17.17 SERUM CONCENTRATION OF 49 PROTEINS IN PATIENTS WITH CHRONIC GASTRITIS BY MULTIPLEX BIOMETRIC IMMUNOASSAY. Digestive and Liver Disease, 2014, 46, S126.	0.9	0



#	ARTICLE	IF	CITATIONS
127	P.16.18 OPTIMIZED CONTRAST-ENHANCED ULTRASONOGRAPHY FOR CHARACTERIZATION OF FOCAL LIVER LESIONS IN CIRRHOSIS: A SINGLE-CENTER RETROSPECTIVE STUDY. Digestive and Liver Disease, 2014, 46, S120.	0.9	0
128	P.06.24 GENDER DIFFERENCE IN DERMATOLOGICAL ADVERSE EFFECTS DURING ANTIBODIES ANTI-TNF ALFA THERAPY IN CHRONIC INFLAMMATORY BOWEL DISEASE. Digestive and Liver Disease, 2014, 46, S78.	0.9	0
129	Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2014, 20, 16841.	3.3	36
130	Skin Adverse Events During Dual and Triple Therapy for HCV-Related Cirrhosis. Hepatitis Monthly, 2014, 14, e16632.	0.2	6
131	Optimized Nonbismuth Quadruple Therapies Cure Most Patients With Helicobacter pylori Infection in Populations With High Rates of Antibiotic Resistance. Gastroenterology, 2013, 145, 121-128.e1.	1.3	177
132	Ultrasound-guided percutaneous biopsy for diagnosis of gastrointestinal lesions. Digestive and Liver Disease, 2013, 45, 816-819.	0.9	12
133	1252 EFFECT OF BARIATRIC SURGERY ON SERUM LEVELS OF GASTROINTESTINAL HORMONES IN OBESE NAFLD PATIENTS. Journal of Hepatology, 2013, 58, S507.	3.7	0
134	Symbiotic formulation in experimentally induced liver fibrosis in rats: intestinal microbiota as a key point to treat liver damage?. Liver International, 2013, 33, 687-697.	3.9	28
135	Hashimoto's Thyroiditis and Entero-Chromaffin-like Cell Hyperplasia: Early Detection and Somatostatin Analogue Treatment. European Journal of Inflammation, 2013, 11, 863-870.	0.5	5
136	Humerus Metastasis From Cholangiocarcinoma: A Case Report. Gastroenterology Research, 2013, 6, 39-41.	1.3	6
137	Secondary Extramedullary Plasmacytoma of the Duodenum: An Unusual Endoscopic Presentation. Gastroenterology Research, 2013, 6, 110-111.	1.3	3
138	Herbal Products: Benefits, Limits, and Applications in Chronic Liver Disease. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-19.	1.2	49
139	993 ALCOHOL CONSUMPTION AMONG ITALIAN YOUNG PEOPLE. A NEW MODALITY OF INTERVIEW: FACEBOOK. Journal of Hepatology, 2012, 56, S388.	3.7	0
140	Coeliac disease and C virus-related chronic hepatitis: a non association. BMC Research Notes, 2012, 5, 533.	1.4	10
141	Efficacy of 5-Day Levofloxacin-Containing Concomitant Therapy in Eradication of Helicobacter pylori Infection. Gastroenterology, 2012, 143, 55-61.e1.	1.3	81
142	Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial. Free Radical Biology and Medicine, 2012, 52, 1658-1665.	2.9	201
143	F-49 A randomized multicentre double-blind vs placebo trial: Evaluation of effect of silybin conjugated with phosphatidylcholine and vitamin E on liver damage in patients with nonalcoholic fatty liver disease. Digestive and Liver Disease, 2011, 43, S108.	0.9	0
144	P.1.123: LEVOFLOXACIN-CONTAINING QUADRUPLE CONCOMITANT THERAPY FOR ERADICATION OF H PYLORI INFECTION. Digestive and Liver Disease, 2011, 43, S188-S189.	0.9	0

#	ARTICLE	IF	CITATIONS
145	Five-Day Quadruple Concomitant Therapy vs Ten-Day Sequential Therapy for Eradication of H. pylori Infection. Gastroenterology, 2011, 140, S-148-S-149.	1.3	2
146	825 SILYBIN CONJUGATED WITH PHOSPHATIDYLCHOLINE AND VITAMIN E IMPROVES LIVER DAMAGE IN PATIENTS WITH NAFLD: THE RESULTS OF A RANDOMIZED MULTICENTRE DOUBLE-BLIND VS PLACEBO TRIAL. Journal of Hepatology, 2011, 54, S330-S331.	3.7	3
147	Colonic angiodysplasia with adenomatous epithelial foci. Journal of Gastrointestinal and Liver Diseases, 2011, 20, 347.	0.9	0
148	Fat: A matter of disturbance for the immune system. World Journal of Gastroenterology, 2010, 16, 4762.	3.3	65
149	Endoscopic diagnosis of secondary rectal teratoma in a young woman with constipation and positive fecal occult blood test. Endoscopy, 2010, 42, E254-E255.	1.8	3
150	Intestinal permeability in patients with chronic liver diseases: Its relationship with the aetiology and the entity of liver damage. Digestive and Liver Disease, 2010, 42, 200-204.	0.9	76
151	P.28 LEVOFLOXACIN-BASED SEQUENTIAL THERAPY VS CLARITHROMYCIN-BASED SEQUENTIAL THERAPY FOR ERADICATION OF H. PYLORI INFECTION. Digestive and Liver Disease, 2010, 42, S112-S113.	0.9	0
152	P.124 A PROBIOTIC TREATMENT AMELIORATES CCL4-INDUCED LIVER FIBROSIS IN RATS. Digestive and Liver Disease, 2010, 42, S147.	0.9	0
153	P.239 FOOD CHOICE AND GASTROINTESTINAL HORMONES IN CHRONIC LIVER DISEASES. Digestive and Liver Disease, 2010, 42, S185.	0.9	0
154	Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut, 2010, 59, 1465-1470.	12.1	132
155	The effect of a new symbiotic formulation on plasma levels and peripheral blood mononuclear cell expression of some pro-inflammatory cytokines in patients with ulcerative colitis: a pilot study. European Review for Medical and Pharmacological Sciences, 2009, 13, 285-93.	0.7	19
156	The Impact of Diet on Liver Fibrosis and on Response to Interferon Therapy in Patients With HCV-Related Chronic Hepatitis. American Journal of Gastroenterology, 2008, 103, 3159-3166.	0.4	17
157	Emerging drugs for non-alcoholic fatty liver disease. Expert Opinion on Emerging Drugs, 2008, 13, 145-158.	2.4	26
158	Clinical Trial on the Efficacy of a New Symbiotic Formulation, Flortec, in Patients With Irritable Bowel Syndrome. Journal of Clinical Gastroenterology, 2008, 42, S218-S223.	2.2	65
159	Drinking habits and risk of altered liver enzymes in the general population of a rural area in Southern Italy. Digestive and Liver Disease, 2007, 39, 748-752.	0.9	13
160	Chronic inflammation and oxidative stress in human carcinogenesis. International Journal of Cancer, 2007, 121, 2381-2386.	5.1	809
161	A case of hepatotoxicity caused by green tea. Free Radical Biology and Medicine, 2007, 43, 474-474.	2.9	36
162	The Effect of a Silybin-Vitamin E-Phospholipid Complex on Nonalcoholic Fatty Liver Disease: A Pilot Study. Digestive Diseases and Sciences, 2007, 52, 2387-2395.	2.3	97

#	ARTICLE	IF	CITATIONS
163	Platelet aggregation is affected by nitrosothiols in patients with chronic hepatitis: <i>In vivo</i> and <i>in vitro</i> studies. World Journal of Gastroenterology, 2007, 13, 3677.	3.3	9
164	Total parenteral nutrition-related gastroenterological complications. Digestive and Liver Disease, 2006, 38, 623-642.	0.9	87
165	Treatment of patients with non-alcoholic fatty liver disease: Current views and perspectives. Digestive and Liver Disease, 2006, 38, 789-801.	0.9	28
166	Management and outcomes of hepatic cirrhosis: Findings from the RING study. Hepatology Research, 2006, 36, 176-181.	3.4	4
167	A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations. Gut, 2006, 55, 901-902.	12.1	72
168	Beneficial Effects of a Probiotic VSL#3 on Parameters of Liver Dysfunction in Chronic Liver Diseases. Journal of Clinical Gastroenterology, 2005, 39, 540-543.	2.2	406
169	Heat shock protein 27 expression in patients with chronic liver damage. Immunobiology, 2005, 209, 729-735.	1.9	17
170	Nutritional state and energy balance in cirrhotic patients with or without hypermetabolism†Multicentre prospective study by the “Nutritional Problems in Gastroenterology” Section of the Italian Society of Gastroenterology (SIGE). Digestive and Liver Disease, 2005, 37, 681-688.	0.9	76
171	Oxidative Stress in Alcoholic Liver Disease: Clinical Studies. , 2005, , 775-783.		0
172	The treatment of NAFLD. European Review for Medical and Pharmacological Sciences, 2005, 9, 299-304.	0.7	15
173	Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver. Digestive and Liver Disease, 2004, 36, 398-405.	0.9	56
174	Oxidative stress in viral and alcoholic hepatitis. Free Radical Biology and Medicine, 2003, 34, 1-10.	2.9	376
175	Gut-liver axis: a new point of attack to treat chronic liver damage?. American Journal of Gastroenterology, 2002, 97, 2144-2146.	0.4	143
176	Alteration of haemostasis in non-metastatic gastric cancer. Digestive and Liver Disease, 2001, 33, 546-550.	0.9	27
177	Does polychemotherapy with 5-fluorouracil, methotrexate, and L-folinic acid influence the selenium, zinc, and copper serum levels in cancer of digestive tract?. Journal of Trace Elements in Experimental Medicine, 2001, 14, 73-79.	0.8	1
178	Relationship of Blood Trace Elements to Liver Damage, Nutritional Status, and Oxidative Stress in Chronic Nonalcoholic Liver Disease. Biological Trace Element Research, 2001, 81, 245-254.	3.5	47
179	Effects of selenium and zinc supplementation on nutritional status in patients with cancer of digestive tract. European Journal of Clinical Nutrition, 2001, 55, 293-297.	2.9	76
180	DRINKING HABITS OF SUBJECTS WITH HEPATITIS C VIRUS-RELATED CHRONIC LIVER DISEASE: PREVALENCE AND EFFECT ON CLINICAL, VIROLOGICAL AND PATHOLOGICAL ASPECTS. Alcohol and Alcoholism, 2000, 35, 296-301.	1.6	108

#	ARTICLE	IF	CITATIONS
181	Increased nitric oxide production as evaluated by nitrosoglutathione levels in patients with chronic liver disease and alcohol abuse. Gastroenterology, 2000, 118, A926.	1.3	0
182	Can dietary intake influence plasma levels of amino acids in liver cirrhosis?. Digestive and Liver Disease, 2000, 32, 611-616.	0.9	7
183	Trace Elements and Chronic Liver Diseases. Journal of Trace Elements in Medicine and Biology, 1997, 11, 158-161.	3.0	64
184	Rare <i>Atg7</i> Genetic Variants Predispose to Severe Fatty Liver Disease. SSRN Electronic Journal, 0, , .	0.4	0
185	Just Drink a Glass of Water? Effects of Bicarbonateâ€“Sulfateâ€“Calciumâ€“Magnesium Water on the Gutâ€“Liver Axis. Frontiers in Pharmacology, 0, 13, .	3.5	4